Anal Cancer Epidemiology Forecast 2025-2034

Anal cancer develops in the anal canal and accounts for less than 5% of gastrointestinal cancers. In 2024, 10,540 new cases were expected along with 2,190 deaths in the United States. Risk factors include human papillomavirus (HPV) infection, smoking, and a weakened immune system. Early detection through screening is vital for improving treatment outcomes. Treatment typically involves surgery, radiation, and chemotherapy.

Anal Cancer Epidemiology Forecast Report Coverage

The “Anal Cancer Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of anal cancer. It projects the future incidence and prevalence rates of anal cancer across various populations. The study covers age, gender, and type as major determinants of the anal cancer-affected population. The report highlights patterns in the prevalence of anal cancer over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of anal cancer in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Anal Cancer: Disease Overview

Anal cancer is a rare malignancy that develops in the tissues of the anus, often linked to human papillomavirus (HPV) infection. Risk factors include smoking, weakened immunity, and chronic anal inflammation. Symptoms may include rectal bleeding, pain, itching, and a lump near the anus. It is more common in women than men, with cases rising globally. Early-stage anal cancer is highly treatable with chemoradiotherapy, while advanced cases may require surgery. Screening and HPV vaccination help reduce risk. Survival rates depend on tumour stage and response to treatment.

Anal Cancer: Treatment Overview

The treatment of anal cancer depends on the stage, tumour size, and overall health of the patient. Chemoradiotherapy (a combination of chemotherapy and radiation therapy) is the primary treatment for most cases, aiming to preserve the anal sphincter. Surgery is considered for persistent or recurrent tumours, particularly abdominoperineal resection (APR) if the cancer does not respond to initial therapy. In advanced cases, systemic chemotherapy may be used. Immunotherapy is emerging as a potential option for metastatic anal cancer. Regular follow-ups are essential to monitor treatment response and detect recurrence early.

Epidemiology

The anal cancer epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for anal cancer by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for anal cancer and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• In 2024, an estimated 10,540 new cases were predicted to be diagnosed in the United States (3,360 men, 7,180 women) with approximately 2,190 deaths (1,000 men, 1,190 women).
• Most cases occur in older adults, with an average diagnosis age in the early 60s.
• Anal cancer is more common in white women and black men.
• The lifetime risk of developing anal cancer is 1 in 500, higher in individuals with specific risk factors.

Country-wise Anal Cancer Epidemiology

The anal cancer epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Anal cancer remains a significant public health concern, with an estimated 10,930 new cases projected in 2025 across both sexes in the United States. The incidence is significantly higher in females, with 7,370 cases than in males (3,560 cases). Mortality rates also reflect a gender disparity, with 2,030 estimated deaths, comprising 1,250 female deaths and 780 male deaths. In the United Kingdom, anal cancer incidence rates are expected to increase by 14% in 2038-2040. Projections indicate that by 2038-2040, approximately 2,400 new cases of anal cancer could be diagnosed in the country, annually.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of anal cancer based on several factors.
• Anal Cancer Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population and the unmet needs of anal cancer are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of anal cancer epidemiology in the 8 major markets?
• What will be the total number of patients with anal cancer across the 8 major markets during the forecast period?
• What was the country-wise prevalence of anal cancer in the 8 major markets in the historical period?
• Which country will have the highest number of anal cancer patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of anal cancer during the forecast period of 2025-2034?
• What are the currently available treatments for anal cancer?
• What are the disease risks, signs, symptoms, and unmet needs of anal cancer?

This product will be delivered within 3-5 business days.